Targeted therapies for melanoma include small molecule inhibitors towards B-RAFV600 and MEK kinases (e.g., Vemurafenib, Dabrafenib, Trametinib, Cobimetinib and Binimetinib) that have been tested as monotherapy or combination treatments [2,3,4,5]. This evidence concerns the gene MAP2K7 and melanoma.